Advanced

Transforming growth factor (TGF)-β levels and unprovoked recurrent venous thromboembolism.

Memon, Ashfaque LU ; Sundquist, Kristina LU ; Wang, Xiao LU ; Svensson, Peter LU ; Sundquist, Jan LU and Zöller, Bengt LU (2014) In Journal of Thrombosis and Thrombolysis 38(3). p.348-354
Abstract
Prediction of recurrence in patients with unprovoked venous thromboembolism (VTE) remains a challenge. Studies of atherosclerosis suggest a protective role of transforming growth factor (TGF)-β. However, the role of TGF-β has not been studied in VTE. The aim of this study was to investigate TGF-β as a predictive marker of recurrent VTE in patients with a first episode of unprovoked VTE. Patients in the Malmö Thrombophilia Study (MATS) were followed after the discontinuation of anticoagulant treatment until the diagnosis of recurrent VTE or the end of the study in December 2008 (mean ± SD 38.5 months ± 27). Among patients with a first episode of unprovoked VTE, we identified 42 patients with recurrent VTE during the follow-up period. Two... (More)
Prediction of recurrence in patients with unprovoked venous thromboembolism (VTE) remains a challenge. Studies of atherosclerosis suggest a protective role of transforming growth factor (TGF)-β. However, the role of TGF-β has not been studied in VTE. The aim of this study was to investigate TGF-β as a predictive marker of recurrent VTE in patients with a first episode of unprovoked VTE. Patients in the Malmö Thrombophilia Study (MATS) were followed after the discontinuation of anticoagulant treatment until the diagnosis of recurrent VTE or the end of the study in December 2008 (mean ± SD 38.5 months ± 27). Among patients with a first episode of unprovoked VTE, we identified 42 patients with recurrent VTE during the follow-up period. Two age- and sex-matched control subjects without recurrent VTE were selected for each patient (n = 84). Plasma levels of the three isoforms of TGF-β (TGF-β1, TGF-β2 and TGF-β3) were quantified simultaneously by TGF-β 3-plex immunoassay. Compared to controls, plasma levels of TGF-β1 and TGF-β2 were significantly lower in patients with recurrent VTE (p < 0.05), whereas no difference was found for TGF-β3. In a multivariate Cox regression analyses, adjusted for inherited thrombophilia, age, sex and BMI, low levels of TGF-β1 [hazard ratio (HR) = 2.2, 95 % confidence interval (CI) 1.1-4.3; p = 0.02] and TGF-β2 (HR = 2.4, 95 % CI 1.2-4.7; p = 0.01) were independently associated with a higher risk of recurrent VTE. We propose TGF-β1 and TGF-β2 as potential predictive markers for recurrence in patients with unprovoked VTE. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Thrombosis and Thrombolysis
volume
38
issue
3
pages
348 - 354
publisher
Springer
external identifiers
  • pmid:24402195
  • wos:000341085300009
  • scopus:84906935584
ISSN
1573-742X
DOI
10.1007/s11239-013-1047-0
language
English
LU publication?
yes
id
fa056ecb-fe91-41d9-a5f8-5363805f8d8a (old id 4291856)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/24402195?dopt=Abstract
date added to LUP
2014-02-06 22:12:58
date last changed
2017-06-04 03:25:18
@article{fa056ecb-fe91-41d9-a5f8-5363805f8d8a,
  abstract     = {Prediction of recurrence in patients with unprovoked venous thromboembolism (VTE) remains a challenge. Studies of atherosclerosis suggest a protective role of transforming growth factor (TGF)-β. However, the role of TGF-β has not been studied in VTE. The aim of this study was to investigate TGF-β as a predictive marker of recurrent VTE in patients with a first episode of unprovoked VTE. Patients in the Malmö Thrombophilia Study (MATS) were followed after the discontinuation of anticoagulant treatment until the diagnosis of recurrent VTE or the end of the study in December 2008 (mean ± SD 38.5 months ± 27). Among patients with a first episode of unprovoked VTE, we identified 42 patients with recurrent VTE during the follow-up period. Two age- and sex-matched control subjects without recurrent VTE were selected for each patient (n = 84). Plasma levels of the three isoforms of TGF-β (TGF-β1, TGF-β2 and TGF-β3) were quantified simultaneously by TGF-β 3-plex immunoassay. Compared to controls, plasma levels of TGF-β1 and TGF-β2 were significantly lower in patients with recurrent VTE (p &lt; 0.05), whereas no difference was found for TGF-β3. In a multivariate Cox regression analyses, adjusted for inherited thrombophilia, age, sex and BMI, low levels of TGF-β1 [hazard ratio (HR) = 2.2, 95 % confidence interval (CI) 1.1-4.3; p = 0.02] and TGF-β2 (HR = 2.4, 95 % CI 1.2-4.7; p = 0.01) were independently associated with a higher risk of recurrent VTE. We propose TGF-β1 and TGF-β2 as potential predictive markers for recurrence in patients with unprovoked VTE.},
  author       = {Memon, Ashfaque and Sundquist, Kristina and Wang, Xiao and Svensson, Peter and Sundquist, Jan and Zöller, Bengt},
  issn         = {1573-742X},
  language     = {eng},
  number       = {3},
  pages        = {348--354},
  publisher    = {Springer},
  series       = {Journal of Thrombosis and Thrombolysis},
  title        = {Transforming growth factor (TGF)-β levels and unprovoked recurrent venous thromboembolism.},
  url          = {http://dx.doi.org/10.1007/s11239-013-1047-0},
  volume       = {38},
  year         = {2014},
}